Quest Diagnostics Partners CDC To Offer Free COVID-19 Laboratory Testing To Underserved Communities
(RTTNews) - Quest Diagnostics (DGX), the provider of diagnostic information services, announced Thursday it is partnering the Centers for Disease Control and Prevention's (CDC) Increasing Community Access to Testing (ICATT) for COVID-19 program. The CDC chose Quest following a competitive bid. However, financial terms were not disclosed.
The program is designed to support free COVID-19 laboratory testing for patients in U.S. communities that have been disproportionately affected by the pandemic.
This will provide qualified uninsured individuals access to Quest Diagnostics' COVID-19 molecular diagnostic testing at approximately 1,200 of its 2,100 patient service centers.
The CDC is harnessing the power of public-private collaboration to broaden access to critical COVID-19 laboratory testing for those most in need.
To qualify, individuals must complete a brief online screening questionnaire via QuestDirect, the consumer-initiated testing service from Quest Diagnostics. Both uninsured and insured individuals two years of age and older are eligible.
For More Such Health News, visit rttnews.com
Haystack Oncology And Lisata Therapeutics Partner To Evaluate Efficacy Of Pancreatic Cancer Therapy
Quest Diagnostics To Acquire Outreach Laboratory Services Of OhioHealth
Quest Diagnostics To Acquire LifeLabs From OMERS In About $985 Mln Deal
Quest Diagnostics Awarded Contract To Assess Burden Of Hepatitis C Virus In U.S By CDC
Quest, Scipher Team Up To Expand Diagnostic Services Access For Patients With Rheumatoid Arthritis
Quest Diagnostics Narrows FY23 Adj. EPS Outlook Range, Boosts Revenue Forecast - Update
Quest Diagnostics Says FDA Grants Breakthrough Designation For Adeno-associated Virus Test
